Ocugen, Inc

1,42

Kursmål for aktien: 6.67 $

Det gennemsnitlige kursmål for Ocugen, Inc aktien er 6.67 $ hvilket viser forventningen til aktien indenfor de næste 12 mdr. aktien er undervurderet, da kursmålet ligger under det aktuelle aktiekurs. Aktien er undervurderet med 369,72 % Aktien forventes derfor at stige og være en god investering.

Om Ocugen, Inc aktien

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania. Læs mere
$ 365M Markedsværdi (Mcap)
$ 6,6M Omsætning
Bioteknologi Industri
USA Handles på børsen
ocugen.com Hjemmeside
Sundhed Sektor